Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL

10 year-survival

Time frame: 10 years

Molecular response (BCR::ABL1 ratio)

Molecular response is assessed using BCR::ABL1 ratio, on bone marrow if available (if not, on blood)

Time frame: At the end of each line of treatment, at each relapse, at 5 years after the last relapse, at 10 years after the last relapse

Hematologic response

Hematologic response is defined by less than 5% of blasts on bone marrow aspiration

Time frame: At the end of each line of treatment, at each relapse, at 5 years after the last relapse, at 10 years after the last relapse

Death date

Time frame: Up to 10 years

Cause of death

Cause of death can be : 1)disease, 2)complications related to treatment except bone marrow transplant, 3)Hematopoietic Stem Cells Transplantation related, 4)other

Time frame: Up to 10 years

Treatment characteristics (treatment name)

Name of chemotherapy or immunotherapy used

Time frame: At day 1 of each new treatment of relapse

Treatment characteristics (treatment dates)

Start date and end date of treatment

Time frame: At day 1 and at the end of each line of treatment of relapse

Treatment characteristics (dose)